triamterene has been researched along with Hypokalemic Periodic Paralysis in 3 studies
Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.
triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.
Hypokalemic Periodic Paralysis: An autosomal dominant familial disorder characterized by recurrent episodes of skeletal muscle weakness associated with falls in serum potassium levels. The condition usually presents in the first or second decade of life with attacks of trunk and leg paresis during sleep or shortly after awakening. Symptoms may persist for hours to days and generally are precipitated by exercise or a meal high in carbohydrates. (Adams et al., Principles of Neurology, 6th ed, p1483)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 46-year-old man with hypokalemic periodic paralysis (HypoPP) and diabetes mellitus (DM) had worsened muscle weakness after acetazolamide (ACZ) treatment." | 7.71 | Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. ( Ichikawa, Y; Igarashi, O; Ikeda, K; Iwasaki, Y; Kinoshita, M; Satoyoshi, E; Yabuki, D, 2002) |
| "A 46-year-old man with hypokalemic periodic paralysis (HypoPP) and diabetes mellitus (DM) had worsened muscle weakness after acetazolamide (ACZ) treatment." | 3.71 | Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. ( Ichikawa, Y; Igarashi, O; Ikeda, K; Iwasaki, Y; Kinoshita, M; Satoyoshi, E; Yabuki, D, 2002) |
| "Primary hypokalemic periodic paralysis is an autosomal dominant skeletal muscle channelopathy." | 1.42 | The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis. ( He, F; Huang, H; Jiang, Y; Ke, Q; Lu, L; Qi, M; Weng, C; Yi, X; Yu, P, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ke, Q | 1 |
| He, F | 1 |
| Lu, L | 1 |
| Yu, P | 1 |
| Jiang, Y | 1 |
| Weng, C | 1 |
| Huang, H | 1 |
| Yi, X | 1 |
| Qi, M | 1 |
| Ikeda, K | 1 |
| Iwasaki, Y | 1 |
| Kinoshita, M | 1 |
| Yabuki, D | 1 |
| Igarashi, O | 1 |
| Ichikawa, Y | 1 |
| Satoyoshi, E | 1 |
| Nemoto, H | 1 |
| Kurihara, T | 1 |
1 review available for triamterene and Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
[Periodic paralysis secondary to urinary or gastrointestinal potassium loss].
Topics: Animals; Diagnosis, Differential; Diarrhea; Digestive System; Drug Therapy, Combination; Humans; Hyp | 2001 |
2 other studies available for triamterene and Hypokalemic Periodic Paralysis
| Article | Year |
|---|---|
The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis.
Topics: Acetazolamide; Adult; Asian People; Calcium Channels; Calcium Channels, L-Type; Female; Humans; Hypo | 2015 |
Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis.
Topics: Acetazolamide; Acidosis, Renal Tubular; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Di | 2002 |